Synthetic biology is the attempt to design novel biological devices to improve life, such as bacteria that can produce energy or drugs cheaply or new biological therapies. But the field also has a potential dark side.
Scientists can order expressly designed chunks of DNA from a number of DNA synthesis companies around the world and then fuse these bits together to create new biological “parts.” And the same technology that could lead to valuable inventions can also be used to make deadly bioweapons – hypothetically, terrorists could order DNA to recreate the smallpox virus or design an even more deadly pathogen. While most experts doubt that fringe groups currently have the ability to pull off such a feat of biological engineering (see “The Knowledge”), scientists worry that, as DNA synthesis technologies quickly become cheaper and more accessible, the possibility of nefarious use will grow.
At the recent Synthetic Biology 2.0 (SB2) conference, held in Berkeley, CA, scientists devoted an entire day to a single topic: the security concerns of the fledgling field. The result was an evolving community declaration outlining how scientists and companies should behave to ensure both openness and security of research.
The researchers pledged, for example, to develop better software to detect when orders for dangerous DNA sequences have been placed with DNA synthesis companies, and they recommended that scientists work only with companies who use such software. Drew Endy, a biological engineer at MIT and one of the organizers of the conference, told Technology Review about these discussions on security and what he hopes to accomplish with the new declarations.
Technology Review: What issues are you most concerned about?
Drew Endy: As we’ve made progress in synthetic biology research during the past few years, we’ve also recognized almost immediately that there are a number of issues at the interface of the technology and society. Briefly, these issues can be organized into four topics: safety and security, ownership and sharing, understanding and perception, and community organization. It is irresponsible to develop any technology without also directly addressing the associated nontechnical issues. For example, today, not all DNA synthesis companies check what they make. This was demonstrated recently by the Guardian, which published a front-page article stating you could order a piece of smallpox DNA through the mail. We tried to dissuade the journalist from going forward with this stunt.
TR: So the community put together some explicit declarations, sort of a set of goals and guidelines, to try to begin to address security practices around DNA synthesis. What are the main points outlined in the declaration?
DE: First, we want to make sure that the use of DNA synthesis technology is subject to the same community and institutional oversight mechanisms that have been used successfully with recombinant DNA work for the past 30 years. The main challenge here is that DNA synthesis technology is becoming easy to access anonymously via the Internet. Thus, we are asking DNA synthesis companies to work together to develop an open framework that can be used to ensure that all synthesis orders are placed by qualified individuals who have proper authority for handling the requested DNA. Because such a framework needs to be used everywhere in order to be effective, we are encouraging individual researchers to patronize DNA synthesis providers that employ the framework. The remainder of the declaration is a call to continue open and constructive dialogs that directly address the remaining topics, for example, ownership and sharing.
TR: Are you calling for an all-out boycott of companies that don’t check what DNA they are synthesizing?
DE: Not yet. The technology for checking orders isn’t perfect and would not be practical for use in some settings, for example, high-volume synthesis of very short DNA fragments. The goal for now is to strongly encourage otherwise competing companies to work together and to coordinate with government and others to solve the problem. As improved methods are developed, implemented, and deployed, we expect that adoption of best practice will be widespread. If it turns out that no progress is made, stronger actions may be warranted.
TR: Another outcome of the discussions is the formation of an industry organization for DNA synthesis companies. What is the vision for this organization?
DE: Everyone running a DNA synthesis company has the same problem. You need to check what you’re making to ensure you’re not unknowingly producing something that could cause harm to either someone in the factory, the person you’re delivering it to, or someone else. The solution to this problem can be shared. And if you share the investment in the technology, you’ll be able to develop better technology than anyone could individually. Effective cooperation and industry leadership are needed to make it work.
TR: What is your role in the nascent organization?
DE: We’re trying to help get the organization off the ground by organizing political support – I think it’s irresponsible for the academic research community to call for something to happen without helping. The organization itself will be independent of academia.
TR: During the recent Synthetic Biology meeting, someone from one of the DNA synthesis companies described how hard it was to get the government’s help in vetting orders. He said he’d received an order containing a potentially dangerous sequence and called several government agencies, trying to determine how to proceed. No one could tell him what to do.
DE: This has been a real challenge in the U.S. for six years. Nobody has been able to identify a point-of-contact within government who could help. It’s one of the obvious reasons for starting an industry group, so that the group provides a centralized point-of-contact for government interaction and, as appropriate, oversight.
TR: A large part of the industry organization’s role will be to guide development of new software. How does the current screening software work?
DE: One example is a piece of software called BlackWatch, developed by Rob Jones at Craic Computing. BlackWatch is a computer program that checks to make sure you’re not unknowingly making a sequence of DNA from the select agent list (a list of pathogens).
TR: What are the limitations of the BlackWatch software?
DE: One limitation is the high false positive rate. If you’re comparing the requested sequence against a set of sequences that includes the entire genome of a pathogenic bacterium, many of those genes look like genes of E. coli [bacteria commonly used in research]. Sorting out what’s actually versus apparently dangerous is slow and expensive. It often requires a PhD to manually make the decision. A second limitation is the fact that it’s naive to ask a computer program looking at DNA sequences to infer the intent of the designer of the DNA sequence. Instead, you want the software nested in a decision-making process. Who is ordering the DNA and where is it being shipped? As important, by asking these questions it helps to ensure that the people designing the DNA and their local community are paying attention to issues of biological safety and security.
TR: Any idea what the new software will look like?
DE: There are a number of basic questions that need to be explored. What makes a sequence of DNA dangerous? Can you detect something natural versus engineered? It’s a research process, so there are lots of ideas on how to go about it.
TR: Some people say the biggest potential comes from clandestine government programs, which would actually have the resources to work with these materials. Will the outlined declaration prevent the latter possibility?
DE: No, it doesn’t directly address the issue that some government might start a biological weapons program. But, indirectly, if we don’t have a vibrant and technically superior open research community, the possibility of future harm from clandestine state programs will certainly increase.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.